Get the Stockscreener App
26.46
0.97%
0.4798
Doximity Inc stock is traded at $26.46, with a volume of 479.93K.
It is up +0.97% in the last 24 hours and up +24.61% over the past month.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
See More
Previous Close:
$25.98
Open:
$25.77
24h Volume:
479.93K
Relative Volume:
0.14
Market Cap:
$4.89B
Revenue:
$637.78M
Net Income/Loss:
$239.40M
P/E Ratio:
22.22
EPS:
1.1909
Net Cash Flow:
$307.21M
1W Performance:
+5.39%
1M Performance:
+24.61%
6M Performance:
-50.24%
1Y Performance:
-55.68%
1-Day Range:
$25.75
$26.49
1-Week Range:
$24.54
$26.45
52-Week Range:
$20.55
$76.51
Doximity Inc Stock (DOCS) Company Profile
Name
Doximity Inc
Sector
Industry
Phone
(650) 549-4330
Address
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, BTSG, TEM, HQY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
26.45 | 4.80B | 637.78M | 239.40M | 307.21M | 1.1909 |
VEEV
Veeva Systems Inc
|
163.65 | 27.15B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
54.17 | 10.63B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
49.36 | 8.95B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
84.15 | 7.17B | 1.31B | 215.20M | 408.32M | 2.4627 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | Truist | Buy → Hold |
| Apr-08-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-09-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-06-26 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Jan-08-26 | Upgrade | Truist | Hold → Buy |
| Dec-15-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Oct-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-25 | Downgrade | Goldman | Neutral → Sell |
| Jul-09-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-02-25 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-07-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-07-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-20-24 | Initiated | Stephens | Equal-Weight |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Nov-15-24 | Initiated | Goldman | Neutral |
| Nov-14-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Nov-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-08-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Nov-08-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-09-24 | Upgrade | Needham | Hold → Buy |
| Jul-18-24 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Apr-25-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Jan-02-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-09-23 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-09-23 | Downgrade | Needham | Buy → Hold |
| Aug-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-01-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-06-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-31-22 | Initiated | Wells Fargo | Overweight |
| Oct-24-22 | Initiated | Evercore ISI | In-line |
| Oct-13-22 | Initiated | BTIG Research | Neutral |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-07-22 | Initiated | Truist | Hold |
| Aug-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-28-22 | Initiated | Berenberg | Buy |
| May-18-22 | Reiterated | BofA Securities | Neutral |
| May-18-22 | Reiterated | Goldman | Buy |
| May-18-22 | Reiterated | Guggenheim | Buy |
| May-18-22 | Reiterated | Jefferies | Buy |
| May-18-22 | Reiterated | Morgan Stanley | Equal-Weight |
| May-18-22 | Reiterated | Needham | Buy |
| Apr-07-22 | Initiated | Guggenheim | Buy |
| Apr-04-22 | Initiated | BofA Securities | Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Dec-14-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-02-21 | Initiated | Jefferies | Buy |
| Nov-17-21 | Initiated | Robert W. Baird | Outperform |
| Nov-10-21 | Reiterated | Canaccord Genuity | Buy |
| Nov-10-21 | Reiterated | Goldman | Neutral |
| Nov-10-21 | Reiterated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Reiterated | Needham | Buy |
| Nov-10-21 | Reiterated | Piper Sandler | Overweight |
| Aug-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-19-21 | Initiated | Canaccord Genuity | Buy |
| Jul-19-21 | Initiated | Goldman | Neutral |
| Jul-19-21 | Initiated | JP Morgan | Overweight |
| Jul-19-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-21 | Initiated | Piper Sandler | Overweight |
| Jul-19-21 | Initiated | Raymond James | Outperform |
| Jul-19-21 | Initiated | SVB Leerink | Outperform |
| Jul-19-21 | Initiated | William Blair | Outperform |
View All
Doximity Inc Stock (DOCS) Latest News
Doximity: Buy Rating Reiterated as Analyst Sees Upside from Depressed Valuation with $49 Price Target Maintained - TipRanks
UBS Group AG Buys 142,408 Shares of Doximity, Inc. $DOCS - MarketBeat
Doximity (DOCS) Soft Guidance and Insider Sales Test the Strength of Its AI Healthcare Story - Yahoo Finance
Doximity (NYSE:DOCS) Director Kira Scherer Wampler Sells 9,000 Shares - MarketBeat
Doximity director Kira Scherer Wampler sells $234,540 of Class A stock - Investing.com UK
Doximity (DOCS) director logs 9,000-share sale and option exercises - Stock Titan
Is Doximity (DOCS) Turning Physician Network Scale Into a Durable AI Platform Advantage? - Sahm
Doximity (DOCS) Q4 2026 Preview: EPS Estimated at $0.28; Reports on May 13 - AlphaStreet
Insights Into Doximity (DOCS) Q4: Wall Street Projections for Key Metrics - Yahoo Finance
Pictet Asset Management Holding SA Sells 735,384 Shares of Doximity, Inc. $DOCS - MarketBeat
Earnings Preview: Doximity to Report Financial Results Post-market on May 13 - Moomoo
Why the Market Dipped But Doximity (DOCS) Gained Today - Yahoo Finance
MSN Money - MSN
DOCS (NYSE: DOCS) files Form 144 to sell 9,000 shares via option - Stock Titan
Doximity Stock Down 40% in 2026: Is the Selloff Building a Multi-Year Entry Opportunity? - TIKR.com
Doximity (DOCS) price target decreased by 31.04% to 44.25 - MSN
Harel Insurance Investments & Financial Services Ltd. Purchases 90,341 Shares of Doximity, Inc. $DOCS - MarketBeat
Doximity (DOCS): Buy, Sell, or Hold Post Q4 Earnings? - Barchart.com
Vanguard Group Inc. Buys 518,916 Shares of Doximity, Inc. $DOCS - MarketBeat
Zacks Industry Outlook Highlights Veeva Systems, Doximity and Omnicell - Yahoo Finance
Doximity, Inc. (DOCS) Stock Analysis: Analyst Ratings Suggest 51% Potential Upside In Healthcare Tech - DirectorsTalk Interviews
Is Doximity, Inc. (DOCS) A Good Stock To Buy Now? - Insider Monkey
Is Doximity (DOCS) a Good Stock to Buy? Bullish Thesis Breakdown - HarianBasis.co
Doximity earnings up next: Can guidance ease valuation pressure? By Investing.com - Investing.com Nigeria
Move Over Doximity — There’s a New Social Network for Doctors - MedCity News
Paul Jorgensen of Doximity Pleads Guilty in $2.5M Insider Trading Case - hannahhowell.com
Assessing Doximity (DOCS) Valuation After Recent Share Price Volatility - Yahoo Finance
JPMorgan Small Cap Equity Fund's Doximity Inc(DOCS) Holding History - GuruFocus
DOCS SEC FilingsDoximity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Should Doximity’s CFO Transition Before Earnings Require Action From Doximity (DOCS) Investors? - simplywall.st
Vanguard reports 6.79M Doximity shares; Schedule 13G shows 5.07% (DOCS) - Stock Titan
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack (NYSE:DOCS) - Seeking Alpha
Doximity Stock at $25: Priced for Decline or Positioned for a Double-Digit Rebound? - TIKR.com
Is It Too Late To Consider Buying Doximity, Inc. (NYSE:DOCS)? - 富途牛牛
Doximity drops as guidance trails consensus - MSN
Doximity Announces Fiscal 2024 Second Quarter Financial Results - Quantisnow
Doximity (DOCS) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Evercore Maintains Doximity(DOCS.US) With Hold Rating, Maintains Target Price $25 - Moomoo
Doximity, Inc. (DOCS) Stock Analysis: A Look at Its 57% Potential Upside and Strong Buy Sentiment - DirectorsTalk Interviews
Doximity CFO resigns; interim finance head continues - msn.com
Doximity reaches $31M settlement in securities litigation lawsuit - MSN
Evercore ISI Group Maintains Doximity (DOCS) Outperform Recommendation - MSN
Doximity (DOCS) stock dips while market gains: Key facts - MSN
Evercore ISI Group downgrades Doximity (DOCS) - MSN
Victory Sustainable World Fund's Doximity Inc(DOCS) Holding History - GuruFocus
Doximity to Release Fiscal 2026 Fourth Quarter and Full Year Results on May 13, 2026 - The Joplin Globe
Raymond James reiterates Strong Buy on Doximity stock amid OpenAI launch By Investing.com - Investing.com India
VY(R) JPMorgan Small Cap Core Equity Portfolio's Doximity Inc(DOCS) Holding History - GuruFocus
Raymond James reiterates Strong Buy on Doximity stock amid OpenAI launch - Investing.com Australia
Doximity Inc Stock (DOCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):